

Bibliography

- 1: Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M. Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan. *Clinicoecon Outcomes Res.* 2012;4:13-9.
- 2: Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. *Neuropsychiatr Dis Treat.* 2012;8:259-66.
- 3: Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M. Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. *Patient Prefer Adherence.* 2011;5:611-7.
- 4: Novick D, Ascher-Svanum H, Haro JM, Bertsch J, Takahashi M. Schizophrenia Outpatient Health Outcomes study: twelve-month findings. *Pragmat Obs Res.* 2012 Jun 6;3:27-40.
- 5: Takahashi M, Nakahara N, Fujikoshi S, Iyo M. Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study. *Pragmat Obs Res.* 2015 Jul 14;6:39-46.
- 6: Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. *Psychiatry Clin Neurosci.* 2011 Feb;65(1):55-63.
- 7: Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. *J Affect Disord.* 2012 Feb;136(3):476-84. doi:
- 8: Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and

efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. *Curr Med Res Opin.* 2012 May;28(5):701-13.

9: Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. *Psychiatry Clin Neurosci.* 2012 Jun;66(4):313-21.

10: Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. *BMC Psychiatry.* 2013 Jan 11;13:20. doi: 10.1186/1471-244X-13-20. Erratum in: *BMC Psychiatry.* 2014;14:313. Erratum in: *BMC Psychiatry.* 2014;14:313.

11: Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. *BMC Psychiatry.* 2013 May 14;13:138.

12: Takahashi M, Goto T, Takita Y, Chung SK, Wang Y, Gau SS. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. *Asia Pac Psychiatry.* 2014 Mar;6(1):62-70. doi: 10.1111/j.1758-5872.2012.00204.x. Epub 2012 Jul 23.

13: Goto T, Hirata Y, Takita Y, Trzepacz PT, Allen AJ, Song DH, Gau SS, Ichikawa H, Takahashi M. Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults With ADHD. *J Atten Disord.* 2017 Jan;21(2):100-109.

14: Hirata Y, Goto T, Takita Y, Trzepacz PT, Allen AJ, Ichikawa H, Takahashi M. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. *Asia Pac Psychiatry.* 2014 Sep;6(3):292-301.

- 15: Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC. Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis. *Psychiatry Clin Neurosci*. 2014 Jul;68(7):498-505. doi
- 16: Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T. One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study. *Pragmat Obs Res*. 2012 Jun 13;3:41-49.
- 17: Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC. Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. *BMC Psychiatry*. 2014 Dec 10;14:313. doi: 10.1186/s12888-014-0313-9. Erratum for: *BMC Psychiatry*. 2013;13:20.
- 18: Lee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW, Park TW, Yook KH, Lee JI, Bahn GH, Hirata Y, Goto T, Takita Y, Takahashi M, Lee S, Treuer T. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder. *Asia Pac Psychiatry*. 2014 Dec;6(4):386-96. doi: 10.1111/appy.12160. Epub 2014 Oct 27
- 19: Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y, Koeda T, Oki J, Saito K, Takeshita K, Allen AJ. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2009 Aug;19(4):341-50.

1. Progress in Psychopharmacology(8)リチウムの作用機序
高橋 道宏
分子精神医学 2(4), 392-395, 2002-10
2. 抗うつ薬の分子薬理作用からみた大うつ病の病態メカニズム (特集 気分障害--分子生物学的アプローチの最新現況報告)
高橋 道宏
分子精神医学 1(2), 145-150, 2001-03

3. 抗うつ薬・ストレスの及ぼすラット脳内 calcineurin mRNA 発現への影響
森信 繁，藤巻 康一郎，高橋 道宏，大谷 浩一，加藤 進昌
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 18(6), 389, 1998-12-25
4. 感情障害発病に関わる cAMP 情報伝達機能変化と遺伝子発現変化：ストレス・抗うつ薬と BDNF mRNA 発現との関連
森信 繁，藤巻 康一郎，高橋 道宏，十束 支朗
精神神経学雑誌 = Psychiatria et neurologia Japonica 98(11), 937-942, 1996-11-25
5. 注意欠陥/多動性障害治療薬 ストラテラカプセル (新薬展望 2010) -- (注目の新薬)
高橋 道宏，丹治 由佳
医薬ジャーナル 46(S1), 64-69, 2010
6. 日本人 ADHD 患者におけるアトモキセチンの有効性と安全性：短期プラセボ対照二重盲検試験および長期継続投与試験のまとめ
後藤 太郎，多喜田 保志，高橋 道宏
小児の精神と神経 50(4), 459-460, 2010-12-30
7. ストラテラ開発の歴史と製剤特性 (ADHD 薬物療法の新時代--コンサータとストラテラ) -- (ストラテラに関する知識と経験)
後藤 太郎，丹治 由佳，高橋 道宏
現代のエスプリ (513), 155-163, 2010-04
8. The UKU side effect rating scale(UKU 副作用評価尺度)日本語版およびその作成経緯
千葉 茂，高橋 道宏
臨床精神薬理 8(12), 1939-1961, 2005-12